225Ac-PSMA617: PSMA targeting alpha-radiation therapy of patients with mCRPC
To evaluate the potential of PSMA targeting 225Ac-PSMA617 as a promising new treatment option for poor prognosis advanced stage mCRPC (metastatic castration-resistant prostate cancer) patients. An appropriate starting activity for clinical application of 225Ac-PSMA617 was defined by preliminary dosimetry modeling. The treatment protocol was further refined by an empirical dose escalation during “compassionate use” in a first group of advanced stage patients. The derived “standard operation procedure” was used to treat a larger group of patients, which now has >6 months of follow up. Here we report our clinical observations in regard to anti-tumor activity as well as acute and mid-term toxicities experienced with this new concept of mCRPC therapy.
KRATOCHWIL Clemens;
BRUCHERTSEIFER Frank;
GIESEL Frederik;
APOSTOLIDIS Christos;
HABERKORN Uwe;
MORGENSTERN Alfred;
2017-08-01
European Commission - Joint Research Centre
JRC106148
Additional supporting files
| File name | Description | File type | |
|---|
